Telix Launches US$550M Convertible Bond Refinancing to Push Debt Out to 2031
Telix Pharmaceuticals launches US$550 million convertible bond refinancing
In its 14 April 2026 announcement, Telix Pharmaceuticals launched a US$550 million convertible notes offering due 2031, representing a proactive refinancing of its existing 2029 convertible bonds. The bonds are being issued by wholly-owned subsidiary Telix Pharmaceuticals (Investments) Inc. and guaranteed by Telix and Telix Pharmaceuticals (US) Inc.
The convertible bonds carry a coupon range of 1.50% to 1.75% with a conversion premium of 35.0% to 37.5%, providing cost-effective, non-dilutive financing until conversion occurs. The offering is being marketed to eligible investors, with final terms to be determined via a bookbuild process expected to complete prior to market open on Wednesday, 15 April 2026.
Dr Christian Behrenbruch, Managing Director and Group CEO
“The refinance of the existing Convertible Bonds represents our proactive approach to capital management. The new Convertible Bonds will continue to provide the business with cost effective financing.”
The refinancing demonstrates Telix’s proactive treasury management approach, extending debt maturity and reducing near-term refinancing risk. The company operates globally across Australia, the United States, United Kingdom, Brazil, Canada, Europe and Japan, maintaining dual listings on the ASX and NASDAQ under the ticker TLX.
When big ASX news breaks, our subscribers know first
What are convertible bonds and why do companies use them?
Convertible bonds are hybrid debt-equity instruments that offer investors fixed income with equity upside through a conversion option. Bondholders receive regular interest payments (the coupon) and can choose to convert their bonds into company shares at a predetermined price, typically set at a premium to the current share price.
Companies favour convertible bonds because they pay lower interest rates than straight debt. Investors accept reduced coupon payments in exchange for the potential to participate in share price appreciation through conversion. For Telix, the 1.50% to 1.75% coupon range is substantially lower than traditional corporate debt rates.
Importantly, convertible bonds are non-dilutive until conversion occurs. Existing shareholders are not diluted unless bondholders choose to convert their bonds into shares. The 35.0% to 37.5% conversion premium means Telix’s share price must rise significantly above the reference price before conversion becomes attractive to bondholders.
Key terms of the new convertible bonds
The convertible bonds will mature in 5 years (2031) and include a 3-year investor put option, allowing bondholders to require early redemption at the end of year three. The bonds are intended to be listed on the Singapore Exchange Securities Trading Limited (SGX-ST), providing international investor access.
The reference share price will be determined by the clearing price of a concurrent delta placement, which facilitates hedging activity by investors. J.P. Morgan Securities plc is acting as Sole Bookrunner on the offering.
| Term | Detail |
|---|---|
| Issue Size | US$550 million |
| Maturity | 5 years (2031) |
| Coupon | 1.50% – 1.75% |
| Conversion Premium | 35.0% – 37.5% |
| Investor Put | End of year 3 |
| Ranking | Direct, unconditional, unsubordinated and unsecured |
| Listing | SGX-ST |
The tight coupon range of 1.50% to 1.75% reflects Telix’s improved credit standing and market confidence in its commercial trajectory. The bonds will rank as direct, unconditional, unsubordinated and unsecured obligations of the issuer and guarantors.
Delta placement and stock borrow facility
Concurrent with the convertible bond offering, J.P. Morgan will execute a delta placement of ordinary shares to facilitate hedging activity by investors. The clearing price per ordinary share under this placement will be used as the reference share price for determining the initial conversion price of the bonds.
The bookbuild process for the delta placement is expected to complete prior to market open on Wednesday, 15 April 2026. J.P. Morgan will determine the manner of conducting the placement in consultation with Telix.
To support the implementation of the offering, Elk River Holdings Pty Ltd as the trustee for The Behrenbruch Family Trust intends to enter into a stock borrow facility with an affiliate of J.P. Morgan. Under this arrangement, the trust will lend a certain number of ordinary shares to J.P. Morgan’s affiliate, which must return the borrowed shares pursuant to the terms of the agreement.
Proceeds to retire existing 2029 convertible bonds
After deduction of commissions, professional fees and administrative expenses, the net proceeds from the offering will be used to repurchase the existing convertible bonds due 2029. Telix is conducting a concurrent reverse bookbuilding process to receive indications of interest from holders of the existing bonds.
The number of existing bonds to be repurchased and the purchase price will be determined through the reverse bookbuilding process. J.P. Morgan is acting as Sole Dealer Manager on the concurrent repurchase.
Use of proceeds:
- Repurchase existing 2029 convertible bonds
- Excess funds for general corporate purposes
The refinancing extends Telix’s debt maturity from 2029 to 2031, improving the company’s capital structure and reducing near-term refinancing risk. The transaction represents proactive liability management that provides financial flexibility for the company’s commercial expansion in radiopharmaceuticals.
The next major ASX story will hit our subscribers first
What this means for Telix shareholders
The convertible bond refinancing maintains current shareholder ownership through non-dilutive financing. Shareholders will not experience immediate dilution, as conversion only occurs if bondholders choose to exercise their option, and only after the share price has risen 35.0% to 37.5% above the reference price.
The low coupon rate of 1.50% to 1.75% reduces interest expense compared to alternative funding sources, preserving capital for operational deployment. By extending debt maturity from 2029 to 2031, Telix gains an additional two years of financial flexibility to execute its commercialisation strategy across multiple geographic markets.
Telix operates a global biopharmaceutical business focused on the development and commercialisation of radiopharmaceuticals for oncology and rare diseases. The company maintains dual listings on the ASX and NASDAQ (both under ticker TLX), with international operations spanning Australia, the United States, United Kingdom, Brazil, Canada, Europe and Japan.
The refinancing demonstrates capital markets confidence in Telix’s credit quality and growth trajectory. The transaction supports the company’s expansion in radiopharmaceuticals without equity dilution, positioning Telix to capitalise on commercial opportunities while maintaining a strengthened balance sheet.
Want to Follow Telix’s Strategic Capital Management Approach?
Telix’s US$550 million convertible bond refinancing demonstrates sophisticated treasury management, extending debt maturity to 2031 whilst maintaining shareholder value through non-dilutive financing. The transaction provides financial flexibility to support the company’s global radiopharmaceutical commercialisation strategy.
To stay informed on Telix’s financial positioning and operational developments, visit the Telix investor centre. Access comprehensive company analysis, project updates, and strategic announcements as the company executes its expansion across multiple international markets.